Patents by Inventor Barbara Enenkel
Barbara Enenkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124604Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.Type: ApplicationFiled: December 26, 2023Publication date: April 18, 2024Applicant: AltruBio Inc.Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
-
Patent number: 11897964Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.Type: GrantFiled: August 30, 2021Date of Patent: February 13, 2024Assignee: AltruBio Inc.Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
-
Publication number: 20210395383Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.Type: ApplicationFiled: August 30, 2021Publication date: December 23, 2021Applicant: AltruBio Inc.Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
-
Patent number: 9708626Abstract: The invention relates to DNA-sequences, especially transcription- or expression-enhancing elements (TE elements) and their use on an expression vector in conjunction with an enhancer, a promoter, a product gene and a selectable marker. TE elements bring about an increase in the expression of the product gene, particularly when stably integrated in the eukaryotic genome, preferably the CHO-DG44 genome.Type: GrantFiled: April 29, 2015Date of Patent: July 18, 2017Assignee: Boehringer Ingelheim International GmbHInventors: Barbara Enenkel, Kerstin Assfalg
-
Patent number: 9708636Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences.Type: GrantFiled: July 28, 2016Date of Patent: July 18, 2017Assignee: Boehringer Ingelheim International GmbHInventor: Barbara Enenkel
-
Publication number: 20160348143Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences.Type: ApplicationFiled: July 28, 2016Publication date: December 1, 2016Inventor: Barbara ENENKEL
-
Patent number: 9493803Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences.Type: GrantFiled: December 19, 2013Date of Patent: November 15, 2016Assignee: Boehringer Ingelheim International GmbHInventor: Barbara Enenkel
-
Patent number: 9249201Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.Type: GrantFiled: December 19, 2013Date of Patent: February 2, 2016Assignee: Boehringer Ingelheim International GmbHInventor: Barbara Enenkel
-
Patent number: 9243053Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.Type: GrantFiled: December 19, 2013Date of Patent: January 26, 2016Assignee: Boehringer Ingelheim International GmbHInventor: Barbara Enenkel
-
Publication number: 20150337333Abstract: The invention relates to DNA-sequences, especially transcription- or expression-enhancing elements (TE elements) and their use on an expression vector in conjunction with an enhancer, a promoter, a product gene and a selectable marker. The invention describes Sequence No. 1 and TE elements TE-01, -02, -03, -04, -06, -07, -08, -10, -11 or -12. Because of their small size, TE-06, TE-07 or TE-08 are particularly preferred. Sequence No. 1 originates from a sequence region located upstream from the coding region of the Ub/S27a gene from CHO cells. TE elements bring about an increase in the expression of the product gene, particularly when stably integrated in the eukaryotic genome, preferably the CHO-DG44 genome. Chromosomal positional effects are thereby overcome, shielded or cancelled out. In this way the proportion of high producers in a transfection mixture and also the absolute expression level are increased up to seven-fold.Type: ApplicationFiled: April 29, 2015Publication date: November 26, 2015Inventors: Barbara ENENKEL, Kerstin ASSFALG
-
Patent number: 9045776Abstract: The invention relates to DNA-sequences, especially transcription- or expression-enhancing elements (TE elements) and their use on an expression vector in conjunction with an enhancer, a promoter, a product gene and a selectable marker. TE elements bring about an increase in the expression of the product gene, particularly when stably integrated in the eukaryotic genome, preferably the CHO-DG44 genome.Type: GrantFiled: July 23, 2010Date of Patent: June 2, 2015Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Barbara Enenkel, Kerstin Sautter
-
Patent number: 8975391Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.Type: GrantFiled: February 22, 2013Date of Patent: March 10, 2015Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Barbara Enenkel
-
Publication number: 20140248665Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.Type: ApplicationFiled: December 19, 2013Publication date: September 4, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Barbara ENENKEL
-
Publication number: 20140248660Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.Type: ApplicationFiled: December 19, 2013Publication date: September 4, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Barbara ENENKEL
-
Publication number: 20140242637Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences.Type: ApplicationFiled: December 19, 2013Publication date: August 28, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Barbara ENENKEL
-
Publication number: 20140234893Abstract: The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.Type: ApplicationFiled: December 19, 2013Publication date: August 21, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Barbara ENENKEL
-
Patent number: 8669109Abstract: A new method for selecting clones and recloning mammalian cells which are of importance for the production of biopharmaceuticals, preferably hamster or mouse myeloma cells, with a high degree of automation and throughput. The invention relates to methods of depositing and replicating single cell clones of the cells in question. The invention also relates to methods of preparing proteins using cells which have been obtained and replicated by single cell deposition as well as compositions which allow the replication of single cells.Type: GrantFiled: October 7, 2010Date of Patent: March 11, 2014Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Ralf Otto, Barbara Enenkel, Juergen Fieder, Thomas Krieg
-
Publication number: 20130251708Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.Type: ApplicationFiled: April 17, 2013Publication date: September 26, 2013Applicant: ABGENOMICS COOPERATIEF U.A.Inventors: STEFAN BASSARAB, BARBARA ENENKEL, PATRICK GARIDEL, HEIDRUN SCHOTT, SANJAYA SINGH, TOBIAS LITZENBURGER
-
Publication number: 20130210074Abstract: The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: April 9, 2013Publication date: August 15, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore FLORIN, Barbara ENENKEL, Martin FUSSENEGGER, Hitto KAUFMANN, Raffaella SANTORO
-
Publication number: 20130209449Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.Type: ApplicationFiled: June 12, 2012Publication date: August 15, 2013Applicant: AbGenomics Cooperatief U.A.Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger